Evidence map›Paper›PMID 41523906›Full record

ArticleCase reports in hematology2026

A Case Report of Non-Neutralizing Acquired Factor V Inhibitor Mimicking Deficiency: Diagnostic Challenges and Therapeutic Implications.

Shreyas Kalantri, Pranali Pachika, Shiva Balasubramanian, Bayan Alquran, Morgan McCoy, Vivek Sharma

Abstract read
In one paragraph

Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shreyas KalantriDivision of Hematology and Oncology, Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA, louisville.edu.ORCID https://orcid.org/0000-0002-6871-024X
Pranali PachikaDivision of Hematology and Oncology, Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA, louisville.edu.ORCID https://orcid.org/0009-0004-5264-5860
Shiva BalasubramanianDepartment of Medicine, University of Louisville, Louisville, Kentucky, USA, louisville.edu.ORCID https://orcid.org/0000-0002-3851-6403
Bayan AlquranDepartment of Pathology and Laboratory Medicine, University of Louisville, Louisville, Kentucky, USA, louisville.edu.ORCID https://orcid.org/0009-0002-2729-315X
Morgan McCoyDepartment of Pathology and Laboratory Medicine, University of Louisville, Louisville, Kentucky, USA, louisville.edu.
Vivek SharmaDivision of Hematology and Oncology, Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA, louisville.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired Factor V (FV) deficiency due to inhibitors is a rare coagulopathy that presents significant diagnostic and therapeutic challenges. We report the case of an 81-year-old male with persistent gross hematuria and severe coagulopathy, marked by prolonged prothrombin time (PT), activated partial thromboplastin time (aPTT), and critically low FV activity (< 1%). Initial mixing studies corrected the coagulation abnormalities, suggesting a deficiency rather than an inhibitor; however, standard therapies failed. Fresh frozen plasma (FFP) did not elevate FV levels, and recombinant activated Factor VII (rFVIIa) did not resolve his symptoms, raising suspicion for a non-neutralizing inhibitor that depletes FV by increasing clearance. Clinical improvement was achieved with platelet transfusions, and his FV level normalized after treatment with rituximab and intravenous immunoglobulin (IVIG). PT and aPTT improved from 60 and > 200 to 12 and 32, respectively. It has remained normal with subsequent maintenance immunosuppression with rituximab. This case illustrates the diagnostic complexity created by non-neutralizing FV inhibitors, which accelerate factor clearance without directly impairing activity. It highlights the critical need for integrating clinical and laboratory findings to guide tailored treatment in managing rare coagulopathies.

Indexed as

acquired Factor V deficiencycoagulopathyFactor V inhibitorhematuriaimmunosuppressive therapyintravenous immunoglobulin (IVIG)non-neutralizing antibodyplatelet transfusionrare bleeding disorderrituximab

Identifiers

PMID41523906
PMCPMC12783055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.